SCHEMBL7530255

SCHEMBL7530255

O=C(NC1=CC(=O)SC1)Nc1cccc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.62
KMT2A Q03164 10/20 0.62
MAPT P10636 9/20 0.62
LMNA P02545 7/20 0.62
HTT P42858 3/20 0.62
ALDH1A1 P00352 2/20 0.62
RAB9A P51151 11/20 0.57
NPC1 O15118 10/20 0.57
L3MBTL1 Q9Y468 2/20 0.53
PAX8 Q06710 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
MAPK1 P28482 1/20 0.50
TP53 P04637 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
NOX1 Q9Y5S8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7515807 0.84 GRM5 (0.48) MAPTLMNAALDH1A1TP53GRM5
SCHEMBL7521962 0.83 ALDH1A1 (0.51) MEN1KMT2AMAPTLMNAHTT
SCHEMBL7524755 0.83 SMN1; SMN2 (0.55) MEN1KMT2AMAPTLMNAHTT
SCHEMBL7520584 0.83 NPC1 (0.55) MEN1KMT2ALMNARAB9ANPC1
SCHEMBL7518438 0.82 EPHX1 (0.61) MEN1KMT2AMAPTLMNAHTT
SCHEMBL7525489 0.81 TP53 (0.59) MEN1KMT2AMAPTLMNAHTT
SCHEMBL7527253 0.81 MAPT (0.60) MEN1KMT2AMAPTLMNAHTT
SCHEMBL7525033 0.79 RAB9A (0.56) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL2682054 0.79 KMT2A (1.00) MEN1KMT2AMAPTLMNAHTT
SCHEMBL29556162 0.77 MEN1 (0.89) MEN1KMT2AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH 2002-05-16 US disclosed
US-6333346-B1 AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 2001-12-25 US disclosed
EP-1009747-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS Roche Diagnostics GmbH (DE) 2000-06-21 EP disclosed
WO-1999012917-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents UTS2R, SRD5A2, SRD5A1 MEN1 3390/4885KMT2A 3288/4885MAPT 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.